Osteoporosis is a systemic skeletal disease characterized by low bone mass and deterioration of bone microarchitecture, with consequent increases bone fragility and risk of fractur ...Citește mai mult
Friday, October 19, 2012, at the Congress of the International Osteoporosis Day was launched BONEXIO -an unique combinat ...Citește mai mult
Bonexio helps to stop the process of bone loss, increasing bone density and reducing the risk of non-vertebral ...
HEALTH ADVISORS is a pharmaceutical company currently active on the Romanian market in the field of: food supplements, OTC and RX medicine (including products in national health programs of the Ministry of Health and the National Health Insurance House), medical devices.
One of Health Advisors business priorities is to develop and consolidate its own brands on the Romanian market. Our projects aim at yearly extensions of our product portfolio as well as the development of a production facility.
Health Advisors owns the Romanian market exclusivity for its vitamin K2 -MK7 (scientific name as menaquinone 7), the new vitamin recognized and protected, one of the most intensively studied in recent years.
Mk7 is the only form of vitamin K2, latest discovery in the field of vitamins, scientifically substantiated by medical studies as essential for bone matrix and cardiovascular system. This is not synthesized by the human body, being produced by biotechnological processes, by extraction of Natto (Japanese traditional food).
1929: Henrik Dam, Danish scientist, discovered vitamin K effect on blood clotting (its name comes from the German word Koagulation).
1939: Isolation of vitamins K1 and K2 – Edward Adelbert Doisy managed to isolate vitamin K. In 1940, in collaboration with Thayler, MacCorquodale, McKnee and Binkley established distinction between vitamins K1 and K2. Although belonging to the same family, vitamins K1 and K2 perform different functions, as will be seen later: while K1 is blood clotting, vitamin K2 is designed to prevent the accumulation of calcium in the arteries (K2 is found in many forms).
1943: Nobel Prize for the discovery of vitamin K – Henrik Dam and Edward Doisy shared the Nobel Prize for Medicine for their work published in 1939 about the structure and chemical nature of vitamin K (K1 and K2).
1975: The first clue about the involvement of vitamin K in bone metabolism - Pettiford and Benson published the study about bone malformations of children born to mothers whose body used vitamin K deficient.
1997: It confirms the role of vitamin K and vitamin K2, especially for bone metabolism.
1997: U.S. diet does not give people enough vitamin K for healthy bone building- Sokoll and its partners found out that the U.S. population does not get enough vitamin K from food to deposit calcium in the bones. Further research will look the same in Europe, indicating that it is a feature of the Western diet (versus the traditional Japanese diet).
2001: The effect of vitamin K on calcification of blood vessels – Schurgers and its partners published study that shows another effect of vitamin K deficiency: calcification of blood vessels. Further research will show that vitamin K2 not only prevents calcification of vessels, but also helps remove calcium deposits already made.
2001: Vitamin K2-MK7 is clearly correlated with the proper use of Calcium in the body - At the end of a 3-year study of 944 women between the ages of 20 and 79 years, Japanese researcher Kaneki and partners conclude that the significant factor for reducing the risk of hip fracture is vitamin K2 as MK7, extracted from traditional Japanese food called “natto”. In 2008, a similar study of Yaegashi will reach the same conclusion, noting in addition that although calcium, magnesium, zinc and vitamin D are important for bone health, vitamin K2 is the key factor for maintaining health bone.
2004: Takes birth the company Nattopharma from Norway - Company name comes from “natto” – traditional Japanese food rich in vitamin K2, used by the manufacturer as a source for the production of food supplements.
2009: Vitamin K2-MK7 from NattoPharma receives approval of Innovative Food Ingredient (Novel Food) in the European Union - in accordance with the regulations of the European Parliament.
2012: In Romania appears Bonexio, supplement formulated for healthy bone construction.Citește mai mult